A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Ovarian cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms e-Volve
- 30 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 30 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.